Swedish Orphan Biovitrum AB (publ) (BIT:1SOBI)

Italy flag Italy · Delayed Price · Currency is EUR
25.22
-0.16 (-0.63%)
At close: Jul 4, 2025
-0.63%
Market Cap8.48B
Revenue (ttm)2.41B
Net Income (ttm)391.48M
Shares Outn/a
EPS (ttm)1.13
PE Ratio21.67
Forward PE17.81
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volumen/a
Openn/a
Previous Close25.38
Day's Rangen/a
52-Week Range22.64 - 28.68
Betan/a
RSI42.83
Earnings DateJul 16, 2025

About BIT:1SOBI

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocy... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1939
Employees 1,806
Stock Exchange Borsa Italiana
Ticker Symbol 1SOBI
Full Company Profile

Financial Performance

In 2024, BIT:1SOBI's revenue was 26.03 billion, an increase of 17.65% compared to the previous year's 22.12 billion. Earnings were 3.89 billion, an increase of 61.27%.

Financial numbers in SEK Financial Statements

News

There is no news available yet.